Gabather AB (Nasdaq First North Growth Market: GABA) today announces that the dispute communicated on 7 December 2020 between Gabather and Smerud Medical Research has been resolved by arbitral award in Gabather’s favour at the Arbitration Institute of the Stockholm Chamber of Commerce (SCC).
For further information, please contact:
Dr Michael-Robin Witt, CEO
Telephone: 073-687 28 39, Email: mrw@gabather.com
This information is such that Gabather AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, by the above contact, for public release at 08.00 CEST, 30 April 2021.
About Gabather AB
Gabather develops the next generation of therapeutics to treat mental illness. The company’s selective GABAA modulators have a unique mechanism of action that may be fundamental for new and effective drugs within major psychiatric diagnoses. Gabather is currently implementing a clinical development programme for its most advanced clinical drug candidate, GT-002, to improve the treatment of depression. Gabather’s GABAA modulators may prove to be effective for the treatment of other diseases that are entirely or partially due to the imbalance of the GABA system such as schizophrenia, psychosis, Alzheimer’s disease and autism. Gabather is listed on Nasdaq’s First North Growth Market. The Company’s Certified Adviser is Erik Penser Bank (Tel: +46 8463 8000, certifiedadviser@penser.se).